Melissa L Johnson Selected Research

Melissa L Johnson Research Topics

Disease

40	Neoplasms (Cancer) 03/2024 - 04/2005
22	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 03/2024 - 06/2011
12	Lung Neoplasms (Lung Cancer) 01/2023 - 05/2011
8	Disease Progression 01/2023 - 07/2011
6	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 11/2023 - 01/2017
5	Neoplasm Metastasis (Metastasis) 12/2023 - 04/2005
5	Adenocarcinoma of Lung 01/2013 - 01/2011
2	Brain Neoplasms (Brain Tumor) 12/2023 - 01/2016
2	Colorectal Neoplasms (Colorectal Cancer) 01/2023 - 10/2022
2	Neutropenia 01/2023 - 01/2023
2	Melanoma (Melanoma, Malignant) 01/2023 - 01/2021
2	Fever (Fevers) 01/2022 - 02/2021
2	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2020 - 08/2015
2	Breast Neoplasms (Breast Cancer) 01/2020 - 04/2005
2	Night Blindness (Nyctalopia) 05/2015 - 07/2014
1	Inflammation (Inflammations) 03/2024
1	Testicular Neoplasms (Testicular Cancer) 01/2023
1	Febrile Neutropenia 01/2023
1	Neuroendocrine Carcinoma 01/2023
1	Fatigue 01/2023
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2023
1	Ovarian Neoplasms (Ovarian Cancer) 01/2023
1	Infections 01/2022
1	Mesothelioma 01/2022
1	Pneumonia (Pneumonitis) 02/2021
1	Chills 02/2021
1	Thyroid Neoplasms (Thyroid Cancer) 01/2021
1	Esophageal Perforation 11/2020
1	Colonic Neoplasms (Colon Cancer) 01/2020

Drug/Important Bio-Agent (IBA)

8	Tyrosine Kinase InhibitorsIBA 12/2023 - 01/2011
7	ErbB Receptors (EGF Receptor)IBA 12/2023 - 01/2011
7	LigandsIBA 11/2023 - 04/2005
6	Biomarkers (Surrogate Marker)IBA 02/2024 - 01/2016
5	durvalumabIBA 03/2024 - 09/2022
5	PlatinumIBA 02/2024 - 01/2017
5	Immunoconjugates (Immunoconjugate)IBA 10/2023 - 01/2017
5	adagrasibIBA 01/2023 - 01/2020
5	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2018 - 05/2011
4	VaccinesIBA 03/2024 - 08/2015
4	Immune Checkpoint InhibitorsIBA 03/2024 - 01/2018
4	B7-H1 AntigenIBA 01/2023 - 08/2017
4	DNA (Deoxyribonucleic Acid)IBA 04/2022 - 01/2011
3	AntigensIBA 01/2023 - 11/2020
3	atezolizumabIBA 01/2022 - 08/2017
2	HLA Antigens (Human Leukocyte Antigens)IBA 03/2024 - 01/2023
2	tremelimumabIBA 03/2024 - 01/2023
2	patritumab deruxtecanIBA 12/2023 - 01/2022
2	InterferonsIBA 01/2023 - 11/2021
2	sotorasibIBA 01/2023 - 01/2021
2	selpercatinibIBA 09/2022 - 01/2021
2	Phosphotransferases (Kinase)IBA 09/2022 - 01/2021
2	Codon (Codons)IBA 04/2022 - 01/2021
2	Cysteine (L-Cysteine)FDA Link 04/2022 - 01/2021
2	Proteins (Proteins, Gene)FDA Link 11/2021 - 04/2005
2	rovalpituzumab tesirineIBA 01/2021 - 01/2017
2	CrizotinibIBA 01/2021 - 01/2020
2	cemiplimabIBA 01/2020 - 01/2018
2	Monoclonal AntibodiesIBA 12/2019 - 08/2017
2	Anaplastic Lymphoma KinaseIBA 01/2018 - 12/2012
2	Gefitinib (Iressa)FDA Link 06/2011 - 05/2011
1	Messenger RNA (mRNA)IBA 03/2024
1	IpilimumabIBA 03/2024
1	NivolumabIBA 03/2024
1	Combined VaccinesIBA 03/2024
1	N 30IBA 12/2023
1	Pemetrexed (MTA)FDA Link 11/2023
1	Protein-Arginine N-Methyltransferases (Methyltransferase, Protein Arginine)IBA 11/2023
1	Surface Antigens (Surface Antigen)IBA 10/2023
1	LCL161IBA 01/2023
1	HLA-A Antigens (HLA-A)IBA 01/2023
1	AMG 757IBA 01/2023
1	Docetaxel (Taxotere)FDA Link 01/2023
1	Topotecan (Hycamtin)FDA LinkGeneric 01/2023
1	Chimeric Antigen ReceptorsIBA 01/2023
1	Circulating Tumor DNAIBA 01/2023
1	mocetinostatIBA 01/2023
1	Histone Deacetylase InhibitorsIBA 01/2023
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2023
1	Amino Acids FDA Link 04/2022
1	Guanosine Diphosphate (GDP)IBA 04/2022
1	Protein Kinases (Protein Kinase)IBA 01/2022
1	tyrosine receptor (receptor, tyrosine)IBA 01/2022
1	RNA (Ribonucleic Acid)IBA 11/2021
1	Peptides (Polypeptides)IBA 01/2021
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2021
1	Glycine (Aminoacetic Acid)FDA LinkGeneric 01/2021
1	Bevacizumab (Avastin)FDA Link 11/2020
1	L-BLP25IBA 11/2020
1	lorlatinibIBA 01/2020
1	tisotumab vedotinIBA 01/2020
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2020
1	Thromboplastin (Tissue Factor)IBA 01/2020
1	Investigational DrugsIBA 01/2020
1	CC ChemokinesIBA 12/2019

Therapy/Procedure

31	Therapeutics 03/2024 - 04/2005
14	Drug Therapy (Chemotherapy) 03/2024 - 08/2011
5	Immunotherapy 02/2024 - 11/2020
2	Radiotherapy 01/2020 - 06/2015
1	AT protocol 11/2021
1	Chemoradiotherapy 11/2020